Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARTVerso 1: Faldaprevir + PegIFN/RBV in Treatment-Naive Genotype 1 HCV
NCT01297270Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2011
- Primary completion
- Apr 2014
- Modality
- Small Molecules, Modified Peptides
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of faldaprevir in hepatitis C (HCV) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Sustained Virologic Response 12 Weeks Post Treatment. Started Apr 2011; status: completed.
02
Drugs
faldaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01297270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01297270.